Loading...
HSChapter 30
U.S. imports of vaccines for human medicine (HS 300241) totaled $871.1M in July 2026, traded with 24 countries.
Vaccines for Human Medicine imports of $871.1M in July 2026 ran 14% above the year-to-date monthly average of $767.2M.
Last updated: July 2026 dataHuman vaccines occupy a uniquely regulated corner of pharmaceutical trade: every imported lot must be released by FDA's Center for Biologics Evaluation and Research (CBER) before distribution, a process that includes lot-release testing independent of the manufacturer's own quality control. Belgium and Ireland are the leading US source countries under this heading, reflecting the presence of major multinational vaccine manufacturers in those markets. All imports enter under a single 10-digit line (3002410000), but the regulatory burden — establishment registration, biologics license, cold-chain documentation, and CBER lot release — makes this one of the most documentation-intensive pharmaceutical import categories. Importers should work closely with regulatory counsel and a licensed customs broker to ensure pre-arrival filings are complete.
AI-written summary of the official U.S. Census Bureau trade figures on this page — verify before relying on it.
265 shipments/mo
CBER lot release is an FDA pre-distribution review in which the agency independently tests or reviews manufacturer data for each production lot of certain biologics, including many vaccines. No lot may be distributed in the US until CBER issues a release letter. Importers must factor this review timeline — which can take several weeks — into their supply-chain planning to avoid distribution delays.
Yes. FDA and CBP expect importers to demonstrate that the cold chain has been maintained from the point of manufacture through port of entry. This typically requires temperature-monitoring records (data loggers), a certificate of analysis, and shipping validation documentation. Breaks in the cold chain can result in FDA detention or refusal of the shipment.
Subheading 2 of 10 in heading 3002
Subheading 300241 · $871.1M of $7.9B
ImportsExports
Imports
$871.1MYoY · Pro
Exports
$458.4MYoY · Pro
12-mo low · imports
YoY · ProThrough July 2026. Source: U.S. Census Bureau.
Imports · July 2026
origin
Belgium and Ireland together supply 71% of it.
customs district
destination
entry
rate provision · imports
55.3% enters free of duty; the effective duty rate is 0.00%.
HS10 import codes under this HS6 parent, each with its own page. Source: U.S. Harmonized Tariff Schedule.
| Code | Description | Import Value | Effective Tariff % | Dutiable Share |
|---|---|---|---|---|
| 3002410000 | Vaccines for Human Medicine, NESOI | $871.1M | 0.00% | 0.00% |
HS10 export codes under this HS6 parent, each with its own page. Source: U.S. Schedule B export classification.
| Code | Description | Export Value |
|---|---|---|
| 3002410000 | Vaccines for Human Medicine, NESOI | $458.4M |
Import lines come from the U.S. Harmonized Tariff Schedule and export lines from Schedule B. The two are numbered by different agencies, so the same 10-digit code can appear in both tables describing a different product.
Supplier Network
Get discovered by U.S. importers searching for HS 300241 — Vaccines for Human Medicine. Be the first supplier listed.